What insurance policy changes affect HCPCS J9228?

There are 7 tracked policy changes affecting HCPCS J9228, including updates from Humana, Florida Blue, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J9228?

Payers that have issued tracked updates for HCPCS J9228 include: Humana, Florida Blue, Aetna, Cigna.

How do I get notified when HCPCS J9228 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J9228. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J9228?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J9228 Insurance Policy Changes

HCPCS J9228 is officially defined as "Injection, ipilimumab, 1 mg." HCPCS J9228 is referenced in 7 tracked payer policy changes from Humana, Florida Blue, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9228 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact
Yervoy® (ipilimumab) (New)
Humana·Effective Sep 1, 2026
Humana Medicaid Indiana has implemented a new prior authorization policy for Yervoy (ipilimumab) effective September 1, 2026, covering seven cancer indications including melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, NSCLC, mesothelioma, and esophageal cancer. The policy establishes specific clinical criteria, approval durations (initial and renewal), and exclusions for each indication. Billing teams must implement prior authorization requirements before this date to ensure claims are not denied.
High impact
Yervoy® (ipilimumab) (New)
Humana·Effective Sep 1, 2026
Humana Medicaid Louisiana has implemented a NEW prior authorization policy for Yervoy (ipilimumab) effective September 1, 2026, covering seven cancer indications (melanoma, RCC, MSI-H colorectal cancer, hepatocellular carcinoma, NSCLC, mesothelioma, and esophageal cancer). The policy establishes specific clinical criteria for initial approval and renewal, with most indications requiring combination therapy with Opdivo (nivolumab) and maximum 4-month authorization periods. Billing teams must immediately identify Yervoy claims and implement prior authorization workflows before the effective date.
High impact
Yervoy® (ipilimumab) (New)
Humana·Effective Sep 1, 2026
Humana Medicaid Ohio has released a NEW prior authorization policy for Yervoy (ipilimumab) effective September 1, 2026, covering seven cancer indications including melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, NSCLC, mesothelioma, and esophageal cancer. All Yervoy requests require prior authorization with specific clinical criteria, performance status requirements (ECOG 0-2), and approval durations capped at 4 months per authorization cycle.
High impact
New Drug Waste Reduction Guideline
Florida Blue·Effective Jun 1, 2026
Florida Blue is implementing a new Drug Waste Reduction Guideline effective June 1, 2026, requiring providers to use optimized doses that align with efficient vial combinations for specific injectable medications. The policy affects prior authorization processes and mandates dose optimization (including rounding down up to 10% when clinically appropriate) to reduce medication waste.
High impact
Talimogene Laherparepvec (Imlygic) (CPB 0900, reviewed 2026-04-14)
Aetna·Effective Apr 14, 2026
Aetna has updated its coverage policy for Talimogene Laherparepvec (Imlygic), an oncolytic viral therapy for melanoma and Merkel cell carcinoma. The policy establishes that precertification is mandatory for all commercial plans through the Aetna GCIT team, with specific approval criteria for melanoma (metastatic, unresectable, limited or borderline resectable lesions) and Merkel cell carcinoma (palliative treatment with prior anti-PD-L1/PD-1 progression). Combination therapy with immune checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab) remains experimental and not covered.
High impact
Fundus Photography (CPB 0539, reviewed 2025-08-21)
Aetna·Effective Aug 21, 2025
Aetna's Fundus Photography policy (CPB 0539) establishes medical necessity criteria for fundus photography (CPT 92250), limiting coverage to two times per year with specific clinical indications. The policy explicitly excludes automated color fundus photography for AMD screening and computer-aided analysis (CPT 0380T), and denies baseline fundus photography before MEK inhibitor therapy initiation. A comprehensive list of experimental/unproven indications is now non-covered.
High impact
Oncology drug dose rounding program: July 7 drug list update
Cigna·Effective Jul 7, 2025
Cigna Healthcare is adding 9 new oncology drugs to their dose rounding program effective July 7, 2025. The program rounds drug doses down to the nearest vial size when within 5-10% of prescribed dose, and all prior authorizations are managed through EviCore.

All billing codes J3590 99213 99214 99212 99202 99203

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Yervoy® (ipilimumab) (New)

Yervoy® (ipilimumab) (New)

Yervoy® (ipilimumab) (New)

New Drug Waste Reduction Guideline

Talimogene Laherparepvec (Imlygic) (CPB 0900, reviewed 2026-04-14)

Fundus Photography (CPB 0539, reviewed 2025-08-21)

Oncology drug dose rounding program: July 7 drug list update